Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Kazia Therapeutics Ltd ADR logo

    Kazia Therapeutics Ltd ADR

    US$11.62

    US$11.1b

    7.64%

    245.86%

    Transparent research score

    MaveScore

    A research prioritization score from 0 to 100. It is model output for watchlist review, not personalized financial advice.

    13 Low confidence Low
    Fundamentals Updating
    Price Jun 10, 2026
    Confidence Low

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    10/16 Partial or delayed snapshot
    Fundamental period Updating Refreshing
    Price snapshot Jun 10, 2026 1 day old
    Input coverage 10/16 Stored fields powering this model output
    Confidence impact 6 gaps Missing fields reduce confidence and can limit signal detail

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    1/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    0/15 Needs Data

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    11/15 Strong

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    1/10 Weak

    Positive model output

    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Kazia Therapeutics Ltd ADR Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

    Kazia Therapeutics Ltd ADR is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Kazia Therapeutics Ltd ADR in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    Check out these key findings about Hub Cyber Security Ltd (HUBC)
    13 minutes ago
    News Image
    Check Out PharmaCyte Biotech Inc (PMCB)’s Trade Data Rather Than the Analysts’ Views
    6 minutes ago
    News Image
    Its Stock Has Paid Off Big Time For Psyence Biomedical Ltd
    6 minutes ago

    Kazia Therapeutics Ltd ADR Competitors

    Kazia Therapeutics Ltd ADR operates in the Biotechnology & Medical Research industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Kazia Therapeutics Ltd ADR

    US$11.62

    US$11.1b

    7.64%

    245.86%